Committed to enforcing competition in the pharmaceutical sector.
Yesterday, we fined Teva €462.6 million for patent misuse and disparagement to delay rival multiple sclerosis medicine for Copaxone.
Our landmark decision will help keep drugs affordable and preserve choice ↓

[2024-11-01 11:00 UTC]